It began with a warning letter, rather quietly.
The letter, which detailed violations so technical they nearly appeared administrative, was sent to Théa Pharma’s president on July 9. Beneath the words, however, was a choice that reverberated throughout pharmacy aisles and medicine cabinets. The FDA had ruled that iVIZIA’s dry eye drops—those tiny, preservative-free bottles next to Systane and Blink—were legally considered drugs. And not ones that are lawful.
The manufacturing quality of the drops, which is still uncontested, was not the subject of that conclusion. It was also unrelated to any increase in negative consequences. What the brand said, how it said it, and the implications for federal classification were all factors to consider.
| Detail | Information |
|---|---|
| Product Name | iVIZIA Sterile Lubricant Eye Drops |
| Manufacturer | Théa Pharma, Inc. |
| FDA Warning Letter Issued | July 9, 2025 |
| Main Issues Identified | Unapproved new drug, misbranded product |
| FDA Violation Sections | 505(a), 301(d), 502(ee) of the FD&C Act |
| Non-Monograph Ingredients | Hyaluronic Acid, Trehalose (advertised as active, not approved) |
| Legal Implication | Cannot be marketed without FDA-approved application |
| Product Status | Not recalled officially; pulled from Amazon and some e-commerce platforms |
| Consumer Safety Risk | No manufacturing safety issues noted |
| Purchase Still Possible | Available at some online pharmacies (e.g., Walmart, Walgreens) |
The problem goes beyond compliance for millions of people who use artificial tears on a daily basis. Reading, working, and even blinking can become a mild form of punishment due to the slow, painful friction caused by dry eye, which is more than just an inconvenience. Products like iVIZIA, which is renowned for its exceptional efficacy in treating digital eye strain, have become commonplace.
However, the FDA clarified that a product goes beyond what is permitted in over-the-counter (OTC) drops the instant it asserts therapeutic benefits from ingredients like hyaluronic acid or trehalose, even though they are listed as inactive.
iVIZIA unintentionally crossed that line when they highlighted those ingredients on their website with phrases like “nature’s moisturizer” and “improves comfort during computer work.” According to these claims, those substances were more than just fillers or support agents; they were active and purposefully used for their therapeutic qualities.
In recent weeks, I observed that although the product was still subtly accessible on Walmart’s digital shelves, it had disappeared from Amazon. There was little fanfare when the changes were announced. Neither an urgent consumer warning nor a dazzling recall were present. Just not there.
Regular users were perplexed by this subtle disappearance because iVIZIA’s ABAK bottle design eliminated the need for preservatives, which many had found to be a reassuring solution, especially for those who were sensitive to them. This bottle was extremely versatile for lens wearers, providing both gentleness and precision in equal measure.
The FDA’s alert concerned marketing compliance rather than safety. The fallout was real, though. Payment processors withdrew their support after online retailers started to flag the product. The infrastructure merely hit the pause button without uttering the word “recall.”
Interestingly, iVIZIA wasn’t by herself. Focus PI and Revitalize, two additional eye drop brands, were also reported for comparable infractions. Additionally, their formulations promoted unapproved active ingredients, just like iVIZIA. Caffeine and taurine were on the list for Revitalize. These were marketed as enhancers, intended to energize weary eyes, but they are uncommon in ophthalmic products.
When marketing is involved, it becomes more difficult to distinguish between substances that are technically inactive and those that behave like drugs. It’s a subtle but very significant difference. Even if the label states otherwise, a substance becomes active in the eyes of the law once you claim it treats or prevents a condition.
That’s where things get especially complicated from a regulatory perspective.
Théa Pharma quickly addressed the issue by removing the triggering claims from its website. Revitalize and other impacted businesses released statements defending their formulations and making the required corrections. Resuming business, cleaning up the language, and getting back in line were their clear objectives.
What most surprised me during this process was how subtly powerful a product’s marketing copy can be—how a few exaggerated adjectives might define a product’s legality.
To put things in perspective, this is not a singular enforcement. Independent trackers claim that more than 75% of over-the-counter eye drops currently sold in the United States technically break the same regulations, frequently promoting the advantages of “inactive” ingredients that aren’t mentioned in the FDA’s OTC monograph.
Years ago, some businesses adopted Alcon’s strategy and began marketing their hydrating agents without looking for monograph updates. Before it wasn’t, it was the standard in the industry. Recent letters from the FDA point to a change, possibly for market leaders who have been operating under the radar as well as for newcomers like Théa.
This could change the terrain if it were applied uniformly.
The next question is whether the FDA will continue to scrutinize the big three: AbbVie, Bausch & Lomb, and Alcon. Otherwise, smaller players might experience an unevenly applied crackdown. After all, if enforcement is to be taken seriously, it must be fair.
The future of iVIZIA appears bright despite the setback. Customers are still very loyal to the product. Additionally, there is a feasible route back if Áa makes an investment in a formal approval process or modifies its marketing to align with the monograph.
It serves as a reminder to patients that even dependable products found on pharmacy shelves are subject to unseen rules. Regulation is about what a brand claims to do, not just what a product actually does.
With some hesitancy, a large number of users have switched to alternative preservative-free options in the interim. Familiarity is comforting, and for many people, iVIZIA has become that over time.
Although there hasn’t been an official recall as of yet, the product is much less readily available. Due to compliance risks identified by payment processors, retailers such as Dry Eye Shop have removed it. Customers become even more confused as a result.
Companies could steer clear of these pitfalls by translating regulatory language into language that consumers can understand. Perhaps clarity—how being incredibly clear in both intention and communication might save more than just face—is the true lesson here, rather than merely labeling. Products may remain on shelves as a result.
Because a bottle of eye drops is at the center of it all. And that bottle is much more than a case study on regulations for those who need it. It’s a cap-sized dose of relief.
